NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Shares of Regeneron Pharmaceuticals have plunged more than 30% over the past six months, but one Wall Street analyst believes ...

Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

马萨诸塞州剑桥市 - 市值5,931万美元的临床阶段肿瘤公司Immuneering Corporation (NASDAQ: IMRX )与Regeneron制药公司达成临床供应协议，评估其主要产品候选药物IMM-1-104与Regeneron的抗PD-1疗法Libtayo（cemiplimab）的联合用药潜力。根据 InvestingPro ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Busà Photography / Getty Images Many people believe that being wealthy means having a nice house, a late-model car, and a summer cottage, but the kind of money possessed by the wealthiest 1% of ...

IMM-1-104 is under clinical development by Immuneering and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer ...

Use your computer. The checklist may not open on tablets or mobile phones. For most Internet browsers, clicking on the link above will ask you what you would like to do with the checklist.

Body Dimensions 137.6 x 65.7 x 9.8 mm (5.42 x 2.59 x 0.39 in) ...

The pharma world , esp the big boys dont play clean .. IMM have now done their job and its now down to a big boys to finish it or delay it .. The conference would have been the place to close the deal ...

IMM-1-104 combined with mGnP shows promising efficacy and tolerability in first-line pancreatic cancer, with a 43% ORR and 86% DCR among seven patients. IMM-1-104 demonstrated target lesion shrinkage ...